- Home
- PHAR vs CCRN Comparison
PHAR vs CCRN Comparison
Compare PHAR & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CCRN
- Stock Information
- Founded
- PHAR 1988
- CCRN 1986
- Country
- PHAR Netherlands
- CCRN United States
- Employees
- PHAR N/A
- CCRN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CCRN Professional Services
- Sector
- PHAR Health Care
- CCRN Consumer Discretionary
- Exchange
- PHAR Nasdaq
- CCRN Nasdaq
- Market Cap
- PHAR 718.1M
- CCRN 447.2M
- IPO Year
- PHAR N/A
- CCRN N/A
- Fundamental
- Price
- PHAR $10.65
- CCRN $13.09
- Analyst Decision
- PHAR Strong Buy
- CCRN Hold
- Analyst Count
- PHAR 3
- CCRN 5
- Target Price
- PHAR $30.00
- CCRN $17.93
- AVG Volume (30 Days)
- PHAR 4.4K
- CCRN 262.4K
- Earning Date
- PHAR 07-31-2025
- CCRN 07-30-2025
- Dividend Yield
- PHAR N/A
- CCRN N/A
- EPS Growth
- PHAR N/A
- CCRN N/A
- EPS
- PHAR N/A
- CCRN N/A
- Revenue
- PHAR $320,708,000.00
- CCRN $1,258,238,000.00
- Revenue This Year
- PHAR $13.31
- CCRN N/A
- Revenue Next Year
- PHAR $7.68
- CCRN $5.69
- P/E Ratio
- PHAR N/A
- CCRN N/A
- Revenue Growth
- PHAR 24.13
- CCRN N/A
- 52 Week Low
- PHAR $6.65
- CCRN $9.58
- 52 Week High
- PHAR $12.61
- CCRN $18.50
- Technical
- Relative Strength Index (RSI)
- PHAR 49.05
- CCRN 43.85
- Support Level
- PHAR $10.46
- CCRN $12.72
- Resistance Level
- PHAR $11.49
- CCRN $13.60
- Average True Range (ATR)
- PHAR 0.36
- CCRN 0.58
- MACD
- PHAR -0.12
- CCRN -0.02
- Stochastic Oscillator
- PHAR 31.46
- CCRN 33.33
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CCRN Cross Country Healthcare Inc. $0.0001 Par Value
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.